StockData
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc. (CRBU) stock

CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3074% below fair value
$0.33−0.01 (-4.29%)

Close on Nov 18, 2026Market cap $34.96MP/E –Yield –

Caribou Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Caribou Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$109.47M. For fiscal 2025 it was -$148.34M. The highest annual figure on record is -$34.31M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$148.34M–
FY2024Dec 31, 2024-$166.62M–
FY2023Dec 31, 2023-$116.06M–
FY2022Dec 31, 2022-$106.40M–
FY2021Dec 31, 2021-$66.98M–
FY2020Dec 31, 2020-$36.12M–
FY2019Dec 31, 2019-$34.31M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$25.34M–
Q1 FY2026Mar 31, 2026-$26.28M–
Q4 FY2025Dec 31, 2025-$28.45M–
Q3 FY2025Sep 30, 2025-$29.40M–
Q2 FY2025Jun 30, 2025-$47.58M–
Q1 FY2025Mar 31, 2025-$42.91M–
Q4 FY2024Dec 31, 2024-$38.88M–
Q3 FY2024Sep 30, 2024-$38.24M–
Q2 FY2024Jun 30, 2024-$43.50M–
Q1 FY2024Mar 31, 2024-$46.00M–
Q4 FY2023Dec 31, 2023-$37.44M–
Q3 FY2023Sep 30, 2023-$14.63M–
Q2 FY2023Jun 30, 2023-$32.87M–
Q1 FY2023Mar 31, 2023-$31.12M–
Q4 FY2022Dec 31, 2022-$30.58M–
Q3 FY2022Sep 30, 2022-$26.54M–
Q2 FY2022Jun 30, 2022-$28.43M–
Q1 FY2022Mar 31, 2022-$20.85M–
Q4 FY2021Dec 31, 2021-$20.41M–
Q3 FY2021Sep 30, 2021-$18.62M–
Q2 FY2021Jun 30, 2021-$15.96M–
Q1 FY2021Mar 31, 2021-$13.18M–
Q4 FY2020Dec 31, 2020-$15.21M–
Q3 FY2020Sep 30, 2020-$8.23M–
Q2 FY2020Jun 30, 2020-$2.26M–
Q1 FY2020Mar 31, 2020-$10.43M–

More Caribou Biosciences figures

See a number that looks wrong?